top of page
News, Events and Updates
Search
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Nov 23, 2022
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Nov 8, 2022
US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Nov 7, 2022
Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress
Oct 17, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
Sep 7, 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 23, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 9, 2022
Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022
Aug 4, 2022
8
9
10
11
12
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
